Supernus
SUPN
Supernus (SUPN) news
Recent news
Supernus: deal includes termination fee of up to $174M
AInvest Wire · Aug 3, 2026Indivior Pharmaceuticals Inc: Supernus must pay co termination fee of $101 mln if the merger agreement is terminated under certain circumstances
AInvest Wire · Aug 3, 2026Supernus shares extend gains to rise 17%, Indivior up 1.7%
AInvest Wire · Aug 3, 2026Supernus shares gain 9.3% on Indivior Pharmaceuticals merger
Supernus Pharmaceuticals (NASDAQ: SUPN) shares rose 9.3% following the announcement of a strategic merger with Indivior Pharmaceuticals, a move expected to enhance Supernus’s portfolio in central nervous system (CNS) therapies. The merger aligns with Supernus’s ongoing strategy to expand its…
AInvest Wire · Aug 3, 2026Supernus 2Q revenue $219.1M, estimate $205.3M
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.